As pharma companies approach a brand’s launch date, the demands on their market access teams increase. On September 17, MMIT’s Ryan Witherington and Carolyn Zele will explain how to determine your drug’s pricing and contracting strategies and establish a plan for communicating its value story. Register to get your access link: https://ow.ly/CW9P50ThM0e.
MMIT (Managed Markets Insight & Technology)’s Post
More Relevant Posts
-
Securing a major acquisition, gaining FDA approval for a cutting-edge therapy, or obtaining Series C funding represent landmark moments for pharmaceutical, provider, and payer firms — but these triumphs come with a variety of challenges. How do you integrate new teams while retaining your core talent? How do you sustain morale during rapid scaling? How do you create a foundation for sustained growth? Our newest guide dives deep into these talent-centric challenges, offering actionable strategies to not just manage, but excel, in the post-milestone phase. We spoke with industry experts from Kaiser Permanente, Nestlé Health Science, Walmart Health, Takeda, and more to learn how to maximize the magic of milestone achievements. Read the guide today: https://bit.ly/42IPTVt
-
-
As companies move closer to launch, the use of RWD and Payer Insights play an important role in helping market access teams establish a commercially focused approach to drive launch excellence. Short read that highlights steps your team can take as you plan for your product's launch. Let me know if there is interest in learning more.
Pharma companies have many market access tasks to complete in the year leading up to launch. MMIT’s Ryan Witherington and Carolyn Zele share six key areas to focus on: https://ow.ly/LfPN50TyV3i
-
It all begins with the patient and determining the optimal administration process for the drug product and its characteristics. Developing a path from clinical to commercialization, early evaluation of drug-device combinations is critical to ensure a patient-centric solution, reduce program risk and optimize time and cost efficiencies. In an exclusive Pharmapack Europe supplement with PMPS, William Welch, Executive Director of Services at PCI Pharma Services, discusses the key considerations for drug-device combination products on the clinical to commercialization journey. Click here for the full article: https://lnkd.in/ep4YiUmW #PatientCentricity #DrugDelivery #CDMO #LetsTalkFuture
-
-
Fierce Pharma's latest report unveils the anticipated pharmaceutical shifts of 2024. Delve into the impending generics and biosimilars competition facing industry leaders. From industry giants to niche players, discover the impending transformations shaping the healthcare landscape. #KrugAssociates #PatentExpirations #HealthcareTrends #PharmaInsights #HealthcareShifts
-
Launching a treatment is a complex process that requires the strategic alignment of each pivotal moment. Join us on 19th March at 3pm (GMT) as Scott Briggs, Putnam, Principal, and a panel of industry experts across Inizio discuss the challenges that are often faced when bringing a treatment to market, and the solutions on how to ensure your product launch journey is tracked for success. Learn more and register here: https://lnkd.in/eiC2z3hs #ProductLaunch #LaunchPlanning #Pharma #Webinar
Key product launch challenges: Creating a successful product launch - Putnam
putassoc.com
-
Payers representing more than 50.5 million commercial lives already engage with specialty benefit managers for at least one therapeutic area. MMIT’s Stephen Callahan explains what this means for #pharma companies—and why the future might include pharma/SBM contracting. Click to read about it in Fierce Pharma: https://lnkd.in/gD85G-BU #SpecialtyBenefitManagers #SBMs #PharmaCompanies #MarketAccess
-
-
See below for Reuters Events Pharma's latest free report, analysing #healthequity strategies across pharmaceutical and healthcare organisations. Definitely worth a download!
Our brand-new Health Equity Strategies Outlook 2024 report is out! Download your free copy now https://lnkd.in/euY8K_7S to see why "79% of pharmaceutical organizations have made equitable access to healthcare a core focus of their health equity strategies." and benchmark your access strategy accordingly. #healthequity #healthcareforall #marketaccess
-
-
🆕 Our latest research into the health equity strategies of pharmaceutical organizations and healthcare providers is now available! Inform your health equity strategy with trusted insights, supported by exclusive data from more than 800 practitioners, including: 📊 Refine your approach to health equity data through third-party providers and interoperability 📣 Ensure your messaging and community outreach approach has the necessary nuance 🤝 Establish standardized metrics and reporting frameworks to ensure closer collaboration Access the report below 👇
Our brand-new Health Equity Strategies Outlook 2024 report is out! Download your free copy now https://lnkd.in/euY8K_7S to see why "79% of pharmaceutical organizations have made equitable access to healthcare a core focus of their health equity strategies." and benchmark your access strategy accordingly. #healthequity #healthcareforall #marketaccess
-
-
For pharma brands, prioritizing which healthcare providers to contact and when is an art form. MMIT’s Jay Shah weighs in on four trends we’re seeing in physician engagement: https://ow.ly/nvFw50RjyHx. #Pharma #HCPs #PharmaceuticalReps #PhysicianOutreach #HealthcareTrends
-
Searching for brave minds to help us reimagine healthcare || Human Resource Specialist - Talent Acquisition | Advanced Data Science Lead at ZS | Ex-Goldman Sachs
ZS’s Cody Powers and Josh Hattem share data on pharma launches and approvals and why clinical trials continue to decline. Read our first portfolio and business development quarterly report: #pharma #pharmatrends #ZSpharmalaunchreport
ZS portfolio and business development quarterly: Q1 2024
